Percutaneous transluminal septal myocardial ablation in drag-resistant hypertrophic obstractive cardiomyopathy: 18-Month follow-up results

Journal of Invasive Cardiology

Volumn 13, Issue 7, 2001, Pages 526-530

  Oomman, Abraham ^a   Ramachandran, Panchapakesan ^a   Subramanyan, Krishnaswami ^a   Kalarickal, Mathew Samuel ^a   Osman, Mohammed Najeeb ^a  

^a APOLLO HOSPITALS   (India)

Author keywords

Hypertrophic obstructive cardiomyopathy; Left ventricular outflow tract gradient; Septal artery ablation

Indexed keywords

ALCOHOL;

ADULT; ARTICLE; CATHETER ABLATION; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MIDDLE AGED;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT;

EID: 0035406739     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marian AJ, Mares A Jr., Kelly DP, et al. Sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 1995;16:368-376.
2. Schwartz K. Familial hypertrophic cardiomyopathy: Nonsense versus missense mutations. Circulation 1995;91:2865-2867.
3. Frank MJ, Abdulla AM, Canedo MI, Saylors RI. Long term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 1978;42:993-1001.
4. Isner JM, Clarke RH, Pandian NG, et al. Laser myoplasty for hypertrophic cardiomyopathy. Am J Cardiol 1984;53:1620-1625.
5. Betocchis Los MA, Piscione F, Boccalatte M, et al. Effects of dual-chamber pacing in hypertrophie cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. Am J Cardiol 1996;77:498-502.
6. Robbins RC, Stinson EB. Long term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;3:586-594.
7. Sigwart N. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
8. Seggewiss H, Gleichmann N, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3 months follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
9. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-972.
10. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785.
11. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127-133.
12. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;33:1071-1075.
13. Fananapazir L, Epstein ND, Curiel RV, et al. Long term results of dual chamber (DDD) pacing in obstructive cardiomyopathy: Evidence of progressive symptomatic and hemodynamic improvement and reduction in left ventricular hypertrophy. Circulation 1994;90:2731-2742.
14. Nishimura RA, Hayes DL, Ilstrup DM, et al. Effect of dual chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: Acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol 1996;27:421-430.
15. Nishimura RA, Trusty JM, Hayes DL, et al. Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy prospective, randomized, double-blend cross-over study. J Am Coll Cardiol 1997;29:435-441.
16. Kappenberger L, Linde C, Daubert C, et al. The PIC Study Group. Pacing in hypertrophic obstructive cardiomyopathy. A randomized cross-over study. Eur Heart J 1997;18:1249-1256.
17. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual chamber pacing as a treatment for drug refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized double-blend cross-over study (M-PATHY). Circulation 1999;2:2927-2933.
18. Linde C, Gadler F, for the PIC Study Group. Does pacemaker implantation have a placebo effect? Results from the PIC Study Group (Abstr). J Am Coll Cardiol 1997;29(Suppl A):74A.
19. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and anti-arrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998;31:1175-1206.
20. Knight C, Kurbaan AS, Seggewiss H, et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1997;95:2075-2081.
21. Faber L, Seggewiss H, Fassbinder D, et al. Identification of the target vessel (TV) in percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic cardiomyopathy by myocardial contrast echocardiography (MCE) (Abstr). Circulation 1997;96(Suppl I):I-639.
22. Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms (Editorial Comment). J Am Coll Cardiol 1998;31:259-269.
23. Gietzen FH, Leuner C, Gerenkamp T, Kuhn H. Katheterinterventionelle Therapie der hypertrophisch obstruktiven Kardiomyopathie durch Alkoholablation des ersten Septalastes der linken Koronarterie (Abstr). Z Kardiol 1996;85(Suppl 2):3.
24. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 1999;47:94-100.
25. Seggewiss H, Faber L, Zienser P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev 1999;7:316-323.
26. Kuhn H, Gietzen FH, Leuner CH, et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Cardiol 2000;89(Suppl 4):IV-41-IV-54.
27. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-2421.